| Ytd | 36.23% | |
| 1y | 11.83% |
| Open | 16.81 | Prev Close | 16.89 | Low | 16.48 | High | 16.95 | Mkt Cap | 1.32B |
| Vol | 581.07K | Avg Vol | 876.64K | EPS | -0.09 | P/E | N/A | Forward P/E | 6.49 |
| Beta | 1.21 | Short Ratio | 7.31 | Inst. Own | 98.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-29 | 50-d Avg | 17.92 | 200-d Avg | 13.67 | 1yr Est | 19.56 |
Integra (IART) reported earnings 30 days ago. What's next for the stock?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the
Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA a
Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the
Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Wei
Integra LifeSciences Holdings Corporation (IART) Q2 2026 Earnings Call Transcript
Breakout stocks BSET, AVAH and IART are trading near 52-week highs after passing technical screens.
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed
Integra LifeSciences NASDAQ: IART reported second-quarter 2026 revenue of $419 million, up 0.8% on a
Integra LifeSciences (IART) came out with quarterly earnings of $0.56 per share, beating the Zacks C
Integra Lifesciences (NASDAQ:IART) is looking for Q3 Adj EPS of $0.53-$0.61 vs $0.56 analyst estimat
Integra Lifesciences (NASDAQ:IART) affirms FY2026 Adj EPS guidance from $2.40-$2.50 to $2.40-$2.50 v
Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.56 per share which beat the ana
PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq
UBS analyst Patrick Wood initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Neutral
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the
Investor litigation firm [url="]Kaskela Law[/url] announces that it is investigating Integra LifeSci
PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigati
Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and
Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ
Integra LifeSciences has climbed 52.1% in a year as growth across both segments, improved execution
BMO Capital analyst Vik Chopra initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Ma
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t
If you are looking for stocks that have gained strong momentum recently but are still trading at rea
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Sell and rai
Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Wei
Dow Jones up 200 points, Rockwell Automation shares rise 10.8% on strong earnings and raised guidanc
Integra Lifesciences (NASDAQ:IART) is looking for Q2 Adj EPS of $0.44-$0.52 vs $0.53 analyst estimat
Integra Lifesciences (NASDAQ:IART) raises FY2026 Adj EPS guidance from $2.30-$2.40 to $2.40-$2.50 vs
Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.54 per share which beat the ana
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and
Top Wall Street analysts changed outlook on top names. See all rating changes at https://www.benzing
Wells Fargo analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight a
Integra Lifesciences (NASDAQ:IART) is looking for Q1 Adj EPS of $0.37-$0.45 vs $0.48 analyst estimat
Integra Lifesciences (NASDAQ:IART) is looking for FY2026 Adj EPS of $2.30-$2.40 vs $2.35 analyst est
Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.83 per share which beat the ana
FDA warns of high-risk device issue with wound and burn care products by Integra LifeSciences, citin
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-wound-and-bu
Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company
Truist Securities analyst Ravi Misra reiterates Integra Lifesciences (NASDAQ:IART) with a Hold an
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Sell and low
JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight a